Cerevel_Therapeutics

Cerevel Therapeutics

Cerevel Therapeutics

Biotechnology company

Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses.[1] Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts.[2]

Quick Facts Company type, Traded as ...

The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital.[3][4]

In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion.[5][6][7]

Pipeline

Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more.[8]

Notable Cerevel drugs and treatments at varying stages of development include:

Approach to Treatment

Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease.[14] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types.[1]

The company has stated its approach to neurotherapy development can be viewed through three key lenses:

References

  1. [1]
    "The Last Frontier of Medicine". Neurology live. 2023-04-21. Retrieved 2024-01-13.
  2. [2]
    Logan, Tim (August 7, 2019). "Pfizer spinoff Cerevel moving into Cambridge Crossing". The Boston Globe. Retrieved 2024-01-13.
  3. [3]
    "Bain Capital And Pfizer Create New CNS Company Cerevel Therapeutics". markets.businessinsider.com. 2024-01-12. Retrieved 2024-01-13.
  4. [4]
    Brodwin, Erin. "Drug giant Pfizer isn't ready to abandon neuroscience — here's its $150-million 'star cluster' strategy for betting on promising brain drug startups". Business Insider. Retrieved 2024-01-13.
  5. [5]
    Constantino, Annika Kim (2023-12-06). "AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion". CNBC. Retrieved 2024-01-13.
  6. [6]
    Armstrong, Annalee (December 6, 2023). "AbbVie adds to neuroscience portfolio with $8.7B deal to acquire Cerevel". Fierce Biotech. Retrieved January 13, 2024.
  7. [7]
    "AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline". AbbVie News Center. Retrieved 2024-01-13.
  8. [8]
    "EMPOWERing the Next Generation". Psychiatric Times. 2023-09-13. Retrieved 2024-01-13.
  9. [9]
    "Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson's Disease – Cerevel Therapeutics". www.cerevel.com. 2020-01-14. Retrieved 2024-01-13.
  10. [10]
    "Emraclidine – Cerevel Therapeutics". www.cerevel.com. 2020-01-04. Retrieved 2024-01-13.
  11. [11]
    "Cerevel Therapeutics Announces Publication of Phase 2a Study Results in Neurology on Its Most Advanced Investigational Epilepsy Treatment – Cerevel Therapeutics". www.cerevel.com. 2019-04-09. Retrieved 2024-01-13.
  12. [12]
    "CVL-871 – Cerevel Therapeutics". www.cerevel.com. 2020-01-02. Retrieved 2024-01-13.
  13. [13]
    "CVL-354, a novel, brain penetrant and selective kappa opioid receptor antagonist – Cerevel Therapeutics". www.cerevel.com. 2022-12-01. Retrieved 2024-01-13.
  14. [14]
    "EX-99". www.sec.gov. Retrieved 2024-01-13.
Share this article:

This article uses material from the Wikipedia article Cerevel_Therapeutics, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.